ArticleIndian journal of pediatrics2026
Clinical Outcomes and Hospitalization Cost of Minimally Invasive Surfactant Therapy vs. INSURE (Intubate-Surfactant-Extubate) Method in Neonates with Respiratory Distress Syndrome.
Article in Indian journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectivesTo compare the clinical outcomes and hospitalization costs of Minimally Invasive Surfactant Therapy (MIST) vs. Intubate-Surfactant-Extubate (INSURE) in preterm infants with RDS.
methodsIn this retrospective comparative study, 113 preterm infants with RDS treated with MIST (n = 54) or INSURE (n = 59) between 2018 and 2024 were included. Clinical data and pre-/post-intervention respiratory parameters (PaO
resultsPost-intervention oxygenation improved significantly in both groups (p <0.001). No statistically significant difference in adjusted total hospitalization cost was observed between the MIST and INSURE groups. In the multivariable linear regression analysis, gestational age and PaO₂ were independently associated with total hospitalization cost, whereas the treatment group was not a significant predictor (p = 0.900).The treatment group (MIST vs. INSURE) showed a lower odds of BPD; however, this association did not reach statistical significance after adjustment (OR = 0.420, p = 0.102).
conclusionsMIST was associated with superior short-term clinical outcomes and lower healthcare costs compared with INSURE for neonatal RDS management. These findings support MIST as a safe, effective, and cost-efficient approach. Further randomized controlled trials are required to confirm these benefits and evaluate long-term outcomes before universal adoption in clinical practice.
Indexed as
Identifiers
42518085What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.